Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (543)	3/29/2000 12:23:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 666

RB - You are correct. Toth's long (mid?) term outlook has not changed: Our long-term outlook for Coulter remains optimistic as we believe that Bexxar will achieve success in the non-Hodgkin?s lymphoma (NHL) marketplace. Additional upside may exist for the stock if the recently issued patent covering radioimmunotherapy for the treatment of NHL results in Coulter receiving royalties on future sales of IDEC Pharmaceuticals? Zevalin when it is commercialized in 2H01.